Gyre Therapeutics (GYRE) Change in Account Payables (2014 - 2026)
Gyre Therapeutics (GYRE) reported Change in Account Payables of $139000.0 for Q1 2026, up 892.86% year-over-year from $14000.0 in Q1 2025, and up 131.1% quarter-over-quarter from -$447000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Change in Account Payables (2014 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 13 years of Change in Account Payables data on file, last reported at $139000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $139000.0, up 892.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $124000.0 (up 159.62% YoY), and the FY2025 annual result was -$1000.0, up 99.59% from the prior year.
- Change in Account Payables improved to $139000.0 in Q1 2026 per GYRE's latest filing, from -$447000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $6.3 million in Q4 2022 and troughed at -$3.7 million in Q2 2022.
- A 5-year average of -$1588.2 and a median of -$23000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables tumbled 227.01% in 2022, then surged 1625.0% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $6.3 million in 2022, then tumbled by 105.38% to -$337000.0 in 2023, then jumped by 43.62% to -$190000.0 in 2024, then tumbled by 135.26% to -$447000.0 in 2025, then jumped by 131.1% to $139000.0 in 2026.
- Business Quant data shows GYRE's Change in Account Payables at $139000.0 in Q1 2026, -$447000.0 in Q4 2025, and $483000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 139,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 139,000.00 |
| Mar 31, 2026 | 139,000.00 |
| Dec 31, 2025 | -447,000.00 |
| Dec 31, 2025 | -447,000.00 |
| Sep 30, 2025 | 483,000.00 |
| Sep 30, 2025 | 483,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | -190,000.00 |
| Dec 31, 2024 | -190,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -23,000.00 |
| Mar 31, 2024 | -23,000.00 |
| Dec 31, 2023 | -337,000.00 |
| Dec 31, 2023 | -337,000.00 |